Nicole A Wilski
Overview
Explore the profile of Nicole A Wilski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
252
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rosenbaum S, Caksa S, Stefanski C, Trachtenberg I, Wilson H, Wilski N, et al.
Mol Cancer Res
. 2023 Oct;
22(2):209-220.
PMID: 37847239
Implications: These data support a role for SOX10 expression altering the response to T cell-mediated cell death and contribute to a broader understanding of the interaction between immune cells and...
2.
Glasheen M, Caksa S, Young A, Wilski N, Ott C, Chervoneva I, et al.
Mol Cancer Ther
. 2023 Jun;
22(9):1087-1099.
PMID: 37343247
Drug tolerance and minimal residual disease (MRD) are likely to prelude acquired resistance to targeted therapy. Mechanisms that allow persister cells to survive in the presence of targeted therapy are...
3.
Vernon M, Wilski N, Kotas D, Cai W, Pomante D, Tiago M, et al.
Mol Cancer Res
. 2022 Aug;
20(12):1811-1821.
PMID: 36044013
Implications: Raptinal can rapidly induce pyroptosis in naïve and BRAFi plus MEKi-resistant melanoma, which may be beneficial for patients who have developed acquired resistance to targeted therapies.
4.
Cai W, Nguyen M, Wilski N, Purwin T, Vernon M, Tiago M, et al.
Cancer Res
. 2022 Jun;
82(14):2625-2639.
PMID: 35657206
Significance: Targeting PDPK1 stimulates antitumor immunity and sensitizes NRAS mutant melanoma to MEK inhibition, providing rationale for the clinical development of a combinatorial approach for treating patients with melanoma.
5.
Rosenbaum S, Wilski N, Aplin A
Cancer Discov
. 2021 Jan;
11(2):266-281.
PMID: 33451983
Unleashing the immune system with immune checkpoint inhibitors (ICI) has significantly improved overall survival for subsets of patients with stage III/IV cancer. However, many tumors are nonresponsive to ICIs, in...
6.
Teh J, Erkes D, Cheng P, Tiago M, Wilski N, Field C, et al.
Cancer Immunol Res
. 2020 Jul;
8(9):1114-1121.
PMID: 32661093
Concurrent MEK and CDK4/6 inhibition shows promise in clinical trials for patients with advanced-stage mutant / solid tumors. The effects of CDK4/6 inhibitor (CDK4/6i) in combination with BRAF/MEK-targeting agents on...
7.
Wilski N, Stotesbury C, Del Casale C, Montoya B, Wong E, Sigal L, et al.
J Immunol
. 2020 Apr;
204(11):2961-2972.
PMID: 32284333
CMV has been proposed to play a role in cancer progression and invasiveness. However, CMV has been increasingly studied as a cancer vaccine vector, and multiple groups, including ours, have...
8.
Wilski N, Del Casale C, Purwin T, Aplin A, Snyder C
J Virol
. 2019 Aug;
93(20).
PMID: 31375579
Cytomegalovirus (CMV) is a ubiquitous betaherpesvirus that infects many different cell types. Human CMV (HCMV) has been found in several solid tumors, and it has been hypothesized that it may...
9.
Wilski N, Snyder C
Vaccines (Basel)
. 2019 Jul;
7(3).
PMID: 31323930
Cytomegalovirus (CMV) is a herpesvirus that establishes a persistent, but generally asymptomatic, infection in most people in the world. However, CMV drives and sustains extremely large numbers of antigen-specific T...
10.
Bisetto S, Whitaker-Menezes D, Wilski N, Tuluc M, Curry J, Zhan T, et al.
Front Oncol
. 2018 Sep;
8:324.
PMID: 30211114
Head and neck squamous cell carcinoma (HNSCC) is the 6th most common human cancer and affects approximately 50,000 new patients every year in the US. The major risk factors for...